Method for controlling differentiation of pluripotent stem cells

US11649433B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-11649433-B2
Application numberUS-201816482160-A
CountryUS
Kind codeB2
Filing dateJan 31, 2018
Priority dateJan 31, 2017
Publication dateMay 16, 2023
Grant dateMay 16, 2023

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present invention relates to a method for controlling differentiation of pluripotent stem cells, which method comprises selecting a laminin or a fragment thereof based on binding affinity for the pluripotent stem cells and inducing differentiation of the pluripotent stem cells in the presence of the laminin or a fragment thereof. Here, the binding affinity for cells can be assessed by time-course observation of the survival rate and motility of the cells. According to the present invention, a cell population containing any desired proportion of differentiated cells can be produced from pluripotent stem cells in a simple manner. The cell population obtained by this production method is very useful for cell therapy-based treatment strategies for diseases.

First claim

Opening claim text (preview).

The invention claimed is: 1. A method for producing corneal epithelial cells, the method comprising differentiating human iPS cells to corneal epithelial cells by: (a) culturing said human iPS cells in a culture medium in contact with a laminin 332E8 fragment to generate a first cell population that has been contacted with said laminin332E8 fragment; (b) culturing said first cell population in a serum free medium in contact with a laminin 332E8 fragment to generate a second cell population; (c) culturing said second cell population of differentiated cells in a corneal differentiation medium, which lacks epidermal growth factor (EGF) or fibroblast growth factor 2 (FGF2) but comprises keratinocyte growth factor (KGF) in contact with a laminin 332E8 fragment to produce a third cell population; and (d) culturing said third cell population of differentiated cells in a corneal epithelial cell maintenance medium, which comprises keratinocyte growth factor (KGF) in contact with a laminin 332E8 fragment to produce corneal epithelial cells. 2. The method of claim 1 further comprising detecting the presence of a marker for corneal epithelial cells with the corneal epithelial cells produced by said method. 3. The method of claim 2 , wherein the marker is E-cadherin, TP63, PAX6, K12, K14, or SSEA4/ITGB4. 4. The method of claim 1 further comprising: (e) isolating the corneal epithelial cells produced by the method; (f) seeding 1×10 5 or more of said corneal epithelial cells isolated in step (e) on a plate, and (g) culturing the seeded cells of step (f) on the plate to confluency to form a corneal epithelial cell sheet. 5. The method of claim 4 , wherein the corneal epithelial cells are isolated by FACS. 6. The method of claim 1 , wherein steps (a), (b), (c) and (d) are performed in a vessel coated with said laminin332E8 fragment. 7. The method of claim 1 , wherein steps (a), (b), (c) and (d) are performed by contacting said iPS cells with a carrier comprising said laminin332E8 fragment. 8. The method of claim 1 , wherein the concentration of said laminin332E8 fragment used in said method is about 0.25-2.0 μg/cm 2 . 9. The method of claim 1 , wherein step (a) is performed for 8-10 days. 10. The method of claim 1 , wherein step (b) is performed for 4 weeks. 11. The method of claim 1 , wherein step (c) is performed for 4 weeks. 12. The method of claim 1 , wherein step (d) is performed for 2-5 weeks. 13. The method of claim 1 , further comprising analyzing for the presence or absence of a marker indicating the presence of an undifferentiated populations of cells in the corneal epithelial cells produced by said method. 14. The method of claim 13 , wherein said marker is LIN28A.

Assignees

Inventors

Classifications

  • Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells · CPC title

  • Fibroblast growth factor [FGF] · CPC title

  • C12N5/0619Primary

    Neurons · CPC title

  • Fibronectin; Laminin · CPC title

  • Proteins not provided for elsewhere · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US11649433B2 cover?
The present invention relates to a method for controlling differentiation of pluripotent stem cells, which method comprises selecting a laminin or a fragment thereof based on binding affinity for the pluripotent stem cells and inducing differentiation of the pluripotent stem cells in the presence of the laminin or a fragment thereof. Here, the binding affinity for cells can be assessed by time-…
Who is the assignee on this patent?
Univ Osaka
What technology area does this patent fall under?
Primary CPC classification C12N5/0619. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue May 16 2023 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 5 related publications on this page (citations in our corpus or others sharing the same primary CPC).